Ustekinumab for the Treatment of Refractory Crohnʼs Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Year: 2016
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Ustekinumab is a fully human monoclonal antibody against IL-12/23. Ustekinumab induced clinical response and maintained higher rate of response than placebo in patients with Crohn's disease (CD). This study aims to assess the effectiveness and safety of ustekinumab in refractory patients with CD in real-life practice. METHODS: Consecutive patients with CD who were treated with subcutaneous ustekinumab between March 2010 and December 2014 were retrospectively included in a multicenter open-label study. Clinical response was defined by Harvey-Bradshaw index score and assessed after the loading doses, 6, 12 months, and last follow-up. RESULTS: One hundred sixteen patients were included, with a median follow-up of 10 months (interquartile range: 5-21). Clinical response after loading ustekinumab was achieved in 97/116 (84%) patients. The clinical benefit at 6, 12 months, and at the end of the follow-up was 76%, 64%, and 58%, respectively. Dose escalation was effective in 8 of 11 (73%) patients. Perianal disease also improved in 11 of 18 (61%) patients with active perianal fistulae. The initial response to ustekinumab and previous use of more than 2 immunosuppressant drugs were associated with a clinical response to ustekinumab maintenance therapy. In contrast, previous bowel resection predicted a long-term failure with ustekinumab. Adverse events were reported in 11 (9.5%) patients, but none required ustekinumab withdrawal. CONCLUSIONS: Subcutaneous ustekinumab is effective and safe in a high proportion of patients with CD that were resistant to conventional immunosuppressant and antitumor necrosis factor drugs.
Source: Inflammatory Bowel Diseases
Institutions: Hospital General Universitario Gregorio Marañón, Health Research Institute of the Balearic Islands, Hospital Universitario de La Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Universitario de León, Hospital Universitari i Politècnic La Fe, Hospital Universitario de Burgos, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Salud Carlos III, Corporació Sanitària Parc Taulí, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Complejo Hospitalario de Salamanca, Hospital Universitario Ramón y Cajal
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: ustekinumab, refractory Crohn's disease
Open Access status: bronze
OpenAlex ID: W2424311920
